118 related articles for article (PubMed ID: 16409423)
41. Effect of antireflux treatment on asthma exacerbations in nonatopic children.
Khoshoo V; Haydel R
J Pediatr Gastroenterol Nutr; 2007 Mar; 44(3):331-5. PubMed ID: 17325553
[TBL] [Abstract][Full Text] [Related]
42. Empiric esomeprazole in the treatment of laryngopharyngeal reflux.
DelGaudio JM; Waring JP
Laryngoscope; 2003 Apr; 113(4):598-601. PubMed ID: 12671413
[TBL] [Abstract][Full Text] [Related]
43. Diagnostic value of the Reflux Disease Questionnaire in general practice.
Aanen MC; Numans ME; Weusten BL; Smout AJ
Digestion; 2006; 74(3-4):162-8. PubMed ID: 17351321
[TBL] [Abstract][Full Text] [Related]
44. The effect of esomeprazole 20 mg twice daily on acoustic and perception parameters of the voice in laryngopharyngeal reflux.
Fass R; Noelck N; Willis MR; Navarro-Rodriguez T; Wilson K; Powers J; Barkmeier-Kraemer JM
Neurogastroenterol Motil; 2010 Feb; 22(2):134-41, e44-5. PubMed ID: 19740116
[TBL] [Abstract][Full Text] [Related]
45. Tegaserod for dyspepsia and reflux symptoms in patients with chronic constipation: an exploratory open-label study.
Zeng J; Zuo XL; Li YQ; Wei W; Lv GP
Eur J Clin Pharmacol; 2007 Jun; 63(6):529-36. PubMed ID: 17468863
[TBL] [Abstract][Full Text] [Related]
46. Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs.
Hawkey CJ; Jones RH; Yeomans ND; Scheiman JM; Talley NJ; Goldstein JL; Ahlbom H; Naesdal J
Aliment Pharmacol Ther; 2007 Apr; 25(7):813-21. PubMed ID: 17373920
[TBL] [Abstract][Full Text] [Related]
47. One-week acid suppression trial in uninvestigated dyspepsia patients with epigastric pain or burning to predict response to 8 weeks' treatment with esomeprazole: a randomized, placebo-controlled study.
van Zanten SV; Flook N; Talley NJ; Vakil N; Lauritsen K; Bolling-Sternevald E; Persson T; Björck E; Svedberg LE;
Aliment Pharmacol Ther; 2007 Sep; 26(5):665-72. PubMed ID: 17697200
[TBL] [Abstract][Full Text] [Related]
48. Randomised clinical trial: the burden of illness of uninvestigated dyspepsia before and after treatment with esomeprazole--results from the STARS II study.
van Zanten SV; Wahlqvist P; Talley NJ; Halling K; Vakil N; Lauritsen K; Flook N; Persson T; Bolling-Sternevald E;
Aliment Pharmacol Ther; 2011 Oct; 34(7):714-23. PubMed ID: 21848799
[TBL] [Abstract][Full Text] [Related]
49. Cost analysis of long-term treatment of patients with symptomatic gastroesophageal reflux disease (GERD) with esomeprazole on-demand treatment or esomeprazole continuous treatment: an open, randomized, multicenter study in Switzerland.
Szucs T; Thalmann C; Michetti P; Beglinger C
Value Health; 2009; 12(2):273-81. PubMed ID: 18783388
[TBL] [Abstract][Full Text] [Related]
50. On-demand proton pump inhibitor therapy in patients with gastro-oesophageal reflux disease.
Pace F; Pallotta S; Bianchi Porro G
Dig Liver Dis; 2002 Dec; 34(12):870-7. PubMed ID: 12643297
[TBL] [Abstract][Full Text] [Related]
51. The impact of treatment for gastro-oesophageal reflux disease on health-related quality of life: a literature review.
Prasad M; Rentz AM; Revicki DA
Pharmacoeconomics; 2003; 21(11):769-90. PubMed ID: 12859219
[TBL] [Abstract][Full Text] [Related]
52. Atypical symptoms of GORD in Belgium: epidemiological features, current management and open label treatment with 40 mg esomeprazole for one month.
Louis E; Jorissen P; Bastens B; D'Haens G; Schoofs N; Burette A; Christiaens P; Tack J;
Acta Gastroenterol Belg; 2006; 69(2):203-8. PubMed ID: 16929616
[TBL] [Abstract][Full Text] [Related]
53. Review article: the opportunities and benefits of extended acid suppression.
Scarpignato C; Pelosini I
Aliment Pharmacol Ther; 2006 Jun; 23 Suppl 2():23-34. PubMed ID: 16700900
[TBL] [Abstract][Full Text] [Related]
54. Results of ambulatory pH monitoring do not reliably predict response to therapy in patients with eosinophilic oesophagitis.
Francis DL; Foxx-Orenstein A; Arora AS; Smyrk TC; Jensen K; Nord SL; Alexander JA; Romero Y; Katzka DA
Aliment Pharmacol Ther; 2012 Jan; 35(2):300-7. PubMed ID: 22111863
[TBL] [Abstract][Full Text] [Related]
55. Treatment of chronic posterior laryngitis with esomeprazole.
Ford C
Laryngoscope; 2006 Sep; 116(9):1717-8; author reply 1718. PubMed ID: 16955013
[No Abstract] [Full Text] [Related]
56. Time to relief of episodic symptoms of gastro-oesophageal reflux disease. A crossover comparison of single doses of the effervescent and standard formulations of ranitidine.
Elm M; Hellke P; Andrén K; Dahl G; Nyth AL
Scand J Gastroenterol; 1998 Sep; 33(9):900-4. PubMed ID: 9759942
[TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetics of esomeprazole following varying intravenous administration rates.
Niazi M; Ahlbom H; Bondarov P; Karlsson AH; Hassan-Alin M; Rydholm H; Röhss K
Basic Clin Pharmacol Toxicol; 2005 Dec; 97(6):351-4. PubMed ID: 16364049
[TBL] [Abstract][Full Text] [Related]
58. On-demand treatment of gastro-oesophageal reflux symptoms: a comparison of ranitidine 75 mg with cimetidine 200 mg or placebo.
Galmiche JP; Shi G; Simon B; Casset-Semanza F; Slama A
Aliment Pharmacol Ther; 1998 Sep; 12(9):909-17. PubMed ID: 9768535
[TBL] [Abstract][Full Text] [Related]
59. Randomised clinical trial: identification of responders to short-term treatment with esomeprazole for dyspepsia in primary care - a randomised, placebo-controlled study.
Meineche-Schmidt V; Christensen E; Bytzer P
Aliment Pharmacol Ther; 2011 Jan; 33(1):41-9. PubMed ID: 21083590
[TBL] [Abstract][Full Text] [Related]
60. Improving quality of magnetic resonance cholangiopancreaticography: esomeprazole versus ranitidine.
Hadidy A; Haroun A; Mahafza W; Barbarawi T; Arafeh F; Shannak M
Hepatogastroenterology; 2009; 56(90):290-3. PubMed ID: 19579584
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
